131 related articles for article (PubMed ID: 27635027)
1. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
J Nucl Med; 2017 Feb; 58(2):266-275. PubMed ID: 27635027
[TBL] [Abstract][Full Text] [Related]
2. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
[TBL] [Abstract][Full Text] [Related]
3. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
[TBL] [Abstract][Full Text] [Related]
4. Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Findlay JM; Gillies RS; Franklin JM; Teoh EJ; Jones GE; di Carlo S; Gleeson FV; Maynard ND; Bradley KM; Middleton MR
Eur Radiol; 2016 Oct; 26(10):3519-33. PubMed ID: 26883329
[TBL] [Abstract][Full Text] [Related]
5. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
Br J Surg; 2017 Mar; 104(4):408-417. PubMed ID: 28093719
[TBL] [Abstract][Full Text] [Related]
6. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
7. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
[TBL] [Abstract][Full Text] [Related]
8. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
10. Association of dynamic contrast-enhanced MRI and
Withey SJ; Owczarczyk K; Grzeda MT; Yip C; Deere H; Green M; Maisey N; Davies AR; Cook GJ; Goh V;
Eur J Surg Oncol; 2023 Oct; 49(10):106934. PubMed ID: 37183047
[TBL] [Abstract][Full Text] [Related]
11. Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.
Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R; Zaman S
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2003-2008. PubMed ID: 31350957
[TBL] [Abstract][Full Text] [Related]
12.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
13. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
14.
Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
16. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
[TBL] [Abstract][Full Text] [Related]
17. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
18. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
19. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
[TBL] [Abstract][Full Text] [Related]
20. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
